Chemistry:Gefapixant
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Trade names | Lyfnua |
Other names | MK-7264 |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C14H19N5O4S |
Molar mass | 353.40 g·mol−1 |
3D model (JSmol) | |
| |
|
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.[1] It acts as an antagonist of the P2RX3 receptor.[2][3][4]
It was approved for medical use in the European Union in September 2023.[1]
Medical uses
Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.[1]
Society and culture
Names
It was named in honour of Geoff Burnstock.[5]
References
- ↑ 1.0 1.1 1.2 1.3 "Lyfnua EPAR". 29 September 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/lyfnua.
- ↑ "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough". Pulmonary Pharmacology & Therapeutics 56: 75–78. June 2019. doi:10.1016/j.pupt.2019.03.006. PMID 30880151.
- ↑ "Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation". British Journal of Pharmacology 176 (13): 2279–2291. July 2019. doi:10.1111/bph.14677. PMID 30927255.
- ↑ "Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications". Expert Opinion on Therapeutic Patents 29 (12): 943–963. December 2019. doi:10.1080/13543776.2019.1693542. PMID 31726893.
- ↑ "The discovery and development of gefapixant". Autonomic Neuroscience 235: 102859. November 2021. doi:10.1016/j.autneu.2021.102859. PMID 34403981.
![]() | Original source: https://en.wikipedia.org/wiki/Gefapixant.
Read more |